ABSTRACT
Introduction Tacrolimus remains central to liver transplantation, yet its narrow therapeutic index and pharmacokinetic variability are associated with increased risk of post-transplant diabetes mellitus (PTDM). While polymorphisms in metabolizing enzymes modulate drug exposure and diabetogenic risk, these relationships have not been systematically integrated through targeted pharmacogenomic approaches.
Objective To systematically evaluate genetic variants in tacrolimus-metabolizing genes and their associations with PTDM through integrated in silico pharmacogenomic analysis.
Methods An in silico analysis was performed, integrating data from public repositories (PharmGKB), curated literature, and functional annotations of genetic variants. Machine learning models were developed using synthetic data generated from literature-derived effect sizes to demonstrate proof-of-concept feasibility. We prioritized genes (CYP3A5, CYP3A4, ABCB1) based on PharmGKB evidence levels, functional impact, and clinical associations with tacrolimus exposure and PTDM risk, incorporating genotype information, drug dosing, and metabolic outcomes.
Results The CYP3A5*1 allele emerged as a key determinant, consistently requiring 1.5- to 2.8-fold higher tacrolimus doses and conferring a significantly elevated risk of PTDM compared to non-expressers, an effect mediated by cumulative drug exposure. In the systematic review and synthetic modeling, carriers of functional CYP3A5 alleles expresser genotypes exhibited a significantly increased PTDM risk relative to non-expressers, demonstrating a clear dose–exposure–toxicity relationship. In contrast, CYP3A4 and ABCB1 showed only suggestive but heterogeneous, evidence of association.
Conclusion This in silico pharmacogenomic study demonstrates a clinically significant association between genetic variability in tacrolimus metabolism and the development of PTDM following liver transplantation. These findings support genotype-guided strategies to optimize immunosuppressive therapy and advance precision medicine in transplant care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
